Budget Amount *help |
¥18,460,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥4,260,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2013: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
Outline of Final Research Achievements |
Interferon (IFN) λ plays an important role in innate immunity to protect against hepatitis C viral (HCV) infection. However, the impact of IFNλs on chronic hepatitis C (CHC) is unknown. We aimed to investigate the mechanism underlying responsiveness to IFN-based therapy in CHC associated with SNPs near IL28B. Intrahepatic expressions of ISGs were significantly up-regulated in nonvirological responders (NRs). IFNλ4 expression was associated with lower IL28B induction in patients with IL28B-unfavorable genotype (p = 0.04) and non-response to IFNα therapy (p = 0.003). Overexpression of IFNλ4 suppressed IL28B induction and promoter activation. These results suggest that impaired induction of IL28B, related to IFNλ4 expression, is associated with non-response to IFNα-based therapy.
|